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The ability of the tumor necrosis factor receptor (TNFR) family member GITR to modulate immune responses has been the
subject of multiple studies. Initially thought to be critically involved in governing functions of regulatory T cells, GITR and its
ligand GITRL have meanwhile been found to modulate the reactivity of various diﬀerent cell types and to inﬂuence a broad
variety of immunological conditions including the immune response against tumors. Not only GITR, but also GITRL is capable
of transducing signals, and the consequences of GITR-GITRL interaction may vary among diﬀerent eﬀector cell types, diﬀer upon
signal transduction via the receptor, the ligand, or both, depend on the level of an ongoing immune response, and even diﬀer
among mice and men. In this paper, we address available data on GITR and its ligand in immune responses and discuss the role
and potential therapeutic modulation of this molecule system in antitumor immunity.
1.Introduction
Many members of the TNFR family and their ligands play
animportantroleinproliferation,diﬀerentiation,activation,
and cell death of both tumor and immune eﬀector cells. In
humans, the TNFR family member GITR was ﬁrst identiﬁed
in 1999 by two independent groups as orthologue of murine
GITR, which had been described two years earlier as a
dexamethasone-inducible molecule in T cells [1–3]. GITR
is also known as AITR (Activation-Inducible TNFR family
member) or TNFRSF18 and is a type I transmembrane
protein with a cysteine-rich extracellular domain, the latter
representing a common feature of the TNFR family. Its
cytoplasmic domain exhibits close homology with that
of the TNFR family members 4-1BB/CD137 and CD27
[3]. While diﬀerent splice variants of GITR have been
described in both men and mice ([4] and GenBank numbers
NM 148901.1, NM 148902.1, NM 004195.2), detailed data
on the expression proﬁle of the various splicing variants are
not available as of yet.
Human GITR ligand (GITRL, TNFSF18, AITR ligand)
was identiﬁed simultaneously with its receptor [1, 2],
whereas its murine orthologue was cloned in 2003 [5, 6].
Like most TNF family ligands, it is a type II transmembrane
protein.AvailabledatasuggestthathumanGITRLisatrimer,
but can also be a monomer or assemble in other multimeric
structures, whereas murine GITRL associates as a dimer [7–
10]. In humans, also a soluble form of GITRL (sGITRL) has
been detected on the protein level [11–13]. The mechanism
by which the soluble form of GITRL is produced, that is, by
shedding of the surface-expressed form, for example, due to
the activity of metalloproteases or upon alternative splicing,
is still unclear.
2. GITRand GITRL ExpressionPattern
On human and murine CD4+CD25+ regulatory T cells
( T r e g ) ,h i g hl e v e l so fG I T Rc a nb ed e t e c t e di ns t e a d y -
state with a further increasing expression upon stimulation
[14–18]. Eﬀector CD4+ and CD8+ T cells express GITR
constitutively at low levels, but rapidly upregulate GITR
expression upon activation [1–3, 15, 17, 19–25]. In mice,
expression of GITR has also been detected in B cells, natural
killer (NK) cells, NKT cells, granulocytes, and macrophages2 Clinical and Developmental Immunology
[5, 15, 25–28], whereas in humans GITR expression has been
described in macrophages and NK cells [27, 29–33]. On
the latter, GITR expression is, alike in T cells, upregulated
following activation. Some nonhematological tissues like
skin and lung have also been found to express GITR mRNA
in mice and humans [1, 34].
Of note, some ex vivo studies revealed diﬀerential GITR
expression patterns on T cells dependent on disease state.
Li et al. reported that CD4+ T cells of patients with
noninfectious uveitis express higher levels of GITR than
those of healthy controls, and expression of GITR correlated
with disease course [18]. In HIV-infected humans, higher
baseline expression of GITR on CD4+ T cells compared to
healthydonorswasobserved[35].InpatientswithWegener’s
granulomatosis, GITR expression on CD4+CD25+ T cells
correlated with disease activity [36]. Lee et al. reported
elevated expression of GITR in patients with active systemic
lupus erythematosus as compared to patients with inactive
disease [37], and children with type I diabetes displayed
diminished mRNA levels of GITR in Treg as compared to
controls [38]. These data indicate that GITR expression and
likely also function may depend on the activity levels of the
respective immune eﬀector cell populations.
The cognate ligand of GITR has, in men, been found in
endothelialcells,dendriticcells(DC),macrophages,andcells
of the eye and can be upregulated on the latter by proin-
ﬂammatory cytokines [1, 2, 39]. Human monocytes were
found to transiently up-regulate GITRL upon stimulation
[40]. Murine GITRL has been detected on DC, monocytes,
macrophages, B cells, endothelial cells, osteoclasts, and
microglia cells [5, 6, 16, 23, 41, 42]. GITRL is absent from
resting T cells, but the data whether it is expressed on T
cells following activation are at least partially conﬂicting
[6, 16, 22]. We demonstrated recently that various tumor cell
l i n e sa sw e l la sp r i m a r ys o l i dt u m o r so fd i ﬀerent histological
origin and patient leukemia cells express substantial levels of
GITRL, and elevated levels of sGITRL are present in sera of
patients with various malignancies [11, 31, 43]. Moreover,
we found that GITRL is upregulated on megakaryocytes
during maturation resulting in substantialGITRLexpression
by platelets ([44] and unpublished data).
3. Consequences of GITRActivation inTCells
As of now, most functional studies with GITR focused on
T cells. The initially described function of GITR was its
ability to protect T cells from activation-induced cell death
(AICD) [1, 3]. Subsequently, several groups demonstrated
that GITR triggering by agonistic antibody, by GITRL
expressed on transfectants, or upon addition of GITRL in
soluble form abrogates suppression of murine CD4+CD25+
Treg [5, 6, 14–16, 45, 46]. Of note, human Treg were
found to maintain their suppressive function after GITR
stimulation with antibody, by GITRL transfected into DC or
recombinant GITRL [47, 48]. While this indicates that GITR
may mediate diﬀerential eﬀects in mice and men, it needs to
be considered that in the mouse studies freshly isolated Treg
were used, while polyclonal populations of CD4+CD25+ T
cells or isolated Treg from cancer patients were employed
in the human system. Thus, diﬀerences in the settings used
to stimulate GITR and/or the investigated cell populations
may have inﬂuenced the functional consequences of GITR-
GITRL interaction. Besides modulating Treg reactivity, the
abilityofGITRtomediatecostimulatorysignalsinresponder
T cells receives increasing attention, and GITR triggering
by sGITRL, agonistic antibody, or GITRL expressed on
transfectants has been shown, among others, to increase
T cell proliferation and cytokine production both in the
human and murine systems [6, 13, 15, 16, 19, 24, 45, 46, 48–
52]. Of note, the eﬀects of GITR costimulation seem to
depend on the strength of the ﬁrst signal, indicating that the
consequences of GITR triggering may be inﬂuenced by the
level of immune activation [19, 50].
Analyses of GITR functions in mouse models were
employed to study the role of this molecule both with regard
to its physiological function and its inﬂuence in various
diseases. GITR
−/− mice are available in several mouse strain
backgrounds; they are viable with an apparently healthy
phenotype and without signiﬁcant deﬁciencies in immune
cell development or numbers [53, 54]. Their T cells show
a phenotype characterized by increased proliferation and a
higher sensitivity to AICD, and their Treg display suppressive
activitycomparabletothatofwildtypemice.Thepercentage
of CD4+CD25+ cells in GITR
−/− mice is slightly decreased
[16, 54, 55]. In line, spleens of transgenic C57BL/6 mice
expressing GITRL cDNA under the control of the CD19
promotor contained up to three times more CD4+foxp3+ T
cellsascomparedtowildtypemice,suggestingaroleofGITR
in the ampliﬁcation of Treg [56].
Despite the initial view of GITR as a direct inhibitor of
Treg function, data obtained in GITR
−/− mice indicate that
induction of responder T cell resistance to Treg-mediated
suppression may be a central mechanism underlying the
eﬀects observed upon GITR signaling [16]. Various exper-
imentally induced autoimmune diseases take an attenu-
ated course in GITR
−/− mice. With regard to collagen-
induced arthritis, Sv129 GITR
−/− mice displayed less joint
inﬂammation and bone erosion than wild type controls.
Additionally, the authors reported lower concentrations of
inﬂammatory mediators and suggested that GITR
−/− mice
show decreased inﬂammatory responses due to reduced
costimulation of eﬀector T cells and sustained suppressive
capacity of Treg [55]. Candida albicans infection was found
to take an attenuated course in the same GITR
−/− mice,
and similar ﬁndings were obtained in models of acute lung
inﬂammation upon pleural injection of carrageenan and
lung injury following intratracheal installation of bleomycin
[53, 57, 58]. Moreover, treatment with agonistic GITR
antibody induced or exacerbated autoimmune gastritis,
collagen-induced arthritis, and experimental autoimmune
encephalomyelitis (EAE) in wild type mice and autoimmune
diabetes in nonobese diabetic (NOD) mice due to stimu-
lation of responder T cells [15, 24, 59, 60]. Of note, the B
cell-speciﬁc GITRL transgenic mice described above showed
delayed onset of EAE [56] indicating that experimental
procedures, that is, GITR triggering by antibody or enforced
expressionofGITRLmayberelevantfordiseasemodulation.Clinical and Developmental Immunology 3
Agonistic GITR antibody also enhanced CD4+ and CD8+
T cell immune responses against herpes simplex virus type
1 as exempliﬁed by increased numbers and cytotoxicity of
virus-speciﬁccytotoxiclymphocytesinBALB/candC57BL/6
mice [23, 61]. In addition, treatment with agonistic GITR
antibody enhanced eﬀector T cell responses and reduced
parasite burden in C57BL/6 mice infected with Leishmania
donovani[62].Heart-transplantedCBAmiceshowincreased
graft rejection, progressive decline in contractile function,
and increased coronary artery vasculopathy if treated with
anti-GITR, which was, in this study, not due to stimulation
of CD4+ or CD8+ eﬀector T cells [63]. Two groups reported
on the eﬀect of agonistic anti-GITR antibody in models
of graft versus host disease (GvHD). Kim and coworkers
reported that GITR stimulation converted chronic to active
GvHD, ameliorated disease symptoms, and aﬀected survival
in (C57BL/6xDBA/2)F1 mice with chronic GvHD upon
transfer of DBA/2 parental cells, and this was due to
modulation of eﬀector T cells [20, 64]. Muriglan et al.
found that GITR stimulation enhanced alloreactive CD8+ T
cell proliferation and function, but decreased reactivity of
alloreactive CD4+ T cells. BALB/c mice transplanted with
T cell-depleted C57BL/6 bone marrow allografts receiving
CD8+ donor T cells displayed increased GvHD morbidity
when treated with agonistic antibody, while recipients of
CD4+ T cells showed a signiﬁcant decrease in GvHD
upon GITR triggering [65]. Taken together, the available
data indicate that GITR may not only mediate diﬀerent
eﬀects in Treg and responder T cells, but also diﬀeren-
tially aﬀects functions of CD4+ and CD8+ eﬀector T
cells, and the consequences of GITR signaling seem to be
largely dependent on the level of the ongoing immune
response. It should be noted that, in the majority of models
studying the eﬀects of GITR stimulation with agonistic
GITR antibody, the observed eﬀects were attributed to
activation of eﬀector T cells and not to abrogation of
the suppressor function of Treg. However, the discussion
whetherimmuneactivationandreversalofTcellsuppression
by GITR activation is due to eﬀects on Treg, responder
T cells, or both is still ongoing (for an excellent review
see [66]).
4. Consequences of GITRActivation in
Non-T Cells
In line with its expression pattern, GITR also inﬂuences
the reactivity of various other cell types than T cells.
Macrophages from both mice and humans were found
to up-regulate ICAM-1 following stimulation with anti-
GITR antibody subsequently resulting in aggregation and
adhesion, and produced enhanced levels of MMP-9, TNF,
IL-8, and MCP-1. Notably, recombinant GITRL induced
weaker cytokine responses in cell lines than the antibody or
even failed to stimulate cytokine production and ICAM-1
r e g u l a t i o ni np r i m a r ym a c r o p h a g e s[ 27, 29].
Hanabuchi and coworkers reported activation of human
NK cells after coculture with plasmacytoid DC (pDC),
which was decreased by addition of an anti-GITRL antibody.
They also reported that cytotoxicity and IFN-γ produc-
tion of NK cells were increased in cultures with GITRL-
expressing transfectants [32]. In contrast, we found that
GITR triggering by GITRL expressed on or released as
soluble form by transfectants reduced NK cell cytotoxicity
and cytokine production. NK reactivity was restored by
blocking GITR with anti-GITR antibody or neutralization
of GITRL by a GITR-Ig fusion protein [11, 31, 43]. Our
results that GITR inhibits the reactivity of human NK cells
were subsequently conﬁrmed by a third group reporting that
GITR triggering reduced NK reactivity and proliferation. Of
note, these investigators did, in contrast to our ﬁndings,
observe increased NK cell apoptosis upon GITR triggering
[33].Thediscrepancyamongtheﬁndingsofthethreegroups
studyingGITRfunctioninhumanNKcellsismostlikelydue
to diﬀering experimental settings (e.g., culture conditions,
source of NK cells, techniques to study NK reactivity, etc.)
and/or reagents. In our hands, the anti-GITR antibody,
but not the anti-GITRL antibody, used by Hanabuchi and
coworkers was capable to block binding of GITR-Ig to
GITRL-expressing transfectants and thus receptor-ligand
interaction. Moreover, cytotoxicity and IFN-γ production of
NK cells were enhanced by the presence of the anti-GITR
antibody in cultures with the GITRL-transfectants, but not
in cultures with the mock controls, which further conﬁrmed
its blocking capacity. The antibody did not directly alter NK
reactivity, as it had no eﬀe c ti nc u l t u r e so fN Kc e l l sw i t h
GITRL-negative targets or on cytokine-induced NK eﬀector
functions.Inaddition,noeﬀectoftheantibodywasobserved
in experiments with GITRL-positive target cells using GITR-
negative NK92 NK cells as eﬀectors. Together, these data
excluded that the anti-GITR antibody employed in our
experiments had agonistic properties and conﬁrmed that its
eﬀects in functional experiments were in fact due to blocking
GITR-GITRL interaction. It seems possible that coculture
of GITRL-expressing cells like pDC with GITR-expressing
NK cells or with potentially agonistic GITRL antibody for
longer time periods, like in the work of Hanabuchi et al.,
might induce reverse signaling into the GITRL-expressing
cellswhich,inturn,couldcausealteredNKcellreactivity.We
further analyzed the eﬀects of triggering of GITR on NK cells
using immobilized recombinant GITRL-Ig in cultures with
GITR-GITRLdouble-negativeK562cells.Thissetting,where
eﬀectsofreversesignallingintoGITRL-expressingtargetsare
excluded, further conﬁrmed the inhibitory eﬀect of GITR
on human NK cells. Of note, both immobilized GITRL-Ig
and target cell-expressed GITRL were found to reduce NK
cell NF-κB activity. This could be prevented by the anti-
GITR antibody and conﬁrmed further that GITR mediates
inhibitory signals in human NK cells.
5.“Reverse Signaling”viaGITRL
Many membrane-bound ligands of the TNF family are
able to communicate bidirectional signals. This was ﬁrst
postulated by Smith et al. in 1994, who suggested a
physiological relevance of the short cytoplasmic domains
because of their high interspecies conservation in diﬀerent4 Clinical and Developmental Immunology
TNF family members [67]. Meanwhile there is an increasing
body of data regarding the consequences of signaling via
ligands of the TNF family, and also on reverse signaling
via GITRL in diﬀerent cell types. In murine DC, treatment
with GITR-Ig conferred suppressive properties, and this
was dependent on the presence of IFN-α. The authors
nicely demonstrated, among others, that GITRL signaling
activatesindoleamine-2,3-dioxygenaseintheDCandsuggest
that modulation of tryptophan catabolism upon GITR-
GITRL interaction may represent an important mechanism
ofactionofanti-inﬂammatorycorticosteroids[68].DCfrom
GITR
−/− mice have been shown to display lower TLR2 and
higher TLR4 expression than DC of wild type mice, and
TLR4 expression was down-regulated by recombinant GITR
protein conﬁrming that GITRL signaling in fact inﬂuences
DC [69]. With macrophages, multiple studies revealed that
signals via GITRL modulate their activity in both mice and
humans. Enhanced release of inﬂammatory mediators such
a s ,M M P - 9 ,T N F ,I L - 1 β, IL-8, and MCP-1, and increased
expression of ICAM-1 and cellular aggregation have been
reported upon GITRL signaling [30, 70]. In addition,
inducible nitric oxide (NO) synthetase and cyclooxygenase-
2 are induced in murine macrophages upon stimulation
with GITR, which results in enhanced secretion of NO and
prostaglandin E2 [71, 72]. On the other hand, GITR was
found to cause apoptosis and G1 phase arrest in murine
macrophages upon binding to GITRL [73]. Of note, not
only healthy but also malignant cells of various origins
release immunomodulatory cytokines such as, TGF-β,I L -
10, and TNF upon GITRL signaling [31, 43]. Together,
these ﬁndings on an immunomodulatory function of GITRL
signaling indicate that GITR-GITRL interaction may cause
multiplediﬀerenteﬀectsdependingontheinvolvedcelltypes
(see also Figure 1), which may serve to explain seemingly
contradicting results of diﬀerent studies.
6. RoleoftheGITR-GITRLMoleculeSystemand
Its Modulation in Antitumor Immunity
In recent years, the role of GITR and its ligand in tumor
immunology and especially the possibility to therapeutically
m od u l a t et h i sm o l ec u l es y s t e ma sam e a n sf o rtr e a ti n gc a n c e r
has received considerable interest. Calmels et al. injected
immunocompetent C57BL/6 mice with B16-F0 tumor cells.
When tumors were palpable, the authors injected adenovirus
vectors leading to overexpression of membrane-bound and
soluble GITRL by the tumors. This resulted in enhanced
tumor inﬁltration by CD4+ and CD8+ T cells. More-
over, expression of membrane-bound and soluble GITRL
led to a clear reduction of tumor volume and increased
animal survival without inducing autoimmunity, and the
investigators further reported that tumor-expressed GITRL
enhanced proliferation of CD4+ and CD8+ eﬀector T cells
in the presence of anti-CD3 in vitro [49]. Similar results
were obtained by other investigators. Cho and coworkers
inoculated GITRL-transfected poorly immunogenic CT26
cells into BALB/c mice and reported that GITRL expression
delayed tumor growth and improved survival of the animals.
Enhanced tumor inﬁltration by CD8+ T cells with increased
eﬀector function was observed, and depletion of CD8+ T
cells abrogated the GITRL-mediated delay in tumor growth.
Moreover, GITRL expression on tumor cells enhanced
proliferation and reduced the numbers of apoptotic CD4+
and CD8+ T cells in vitro [50]. Piao and coworkers injected
GITRL-transfectedcelllinesofdiﬀerentoriginandstrainand
the respective parental controls into syngeneic mice. They
found that the parental tumors grew progressively, while
GITRL-expressing tumors regressed, and rechallenge of mice
previously injected with GITRL-expressing cancer cells with
the parental cell lines did not result in tumor growth.
This study also conﬁrmed the central role of CD8+ T cells
for the growth reduction observed with GITRL-expressing
tumorcells.Interestingly,theauthorsdemonstratedthatTreg
contribute to tolerance to GITRL-negative tumors, while in
a setting with GITRL-expressing tumor cells, CD8+ T cell
eﬀector functions overcome their regulatory function [42].
Nishikawa and coworkers immunized BALB/c mice with
plasmids encoding a tumor rejection antigen and GITRL.
They observed a 10-fold increase in the numbers of speciﬁc
T cells and demonstrated that GITR signaling directly
acted on CD8+ T cells, and, in a CMS5 sarcoma model,
GITRL inhibited tumor growth which was dependent on
the presence of CD8+, but not CD4+ T cells. Moreover, the
investigators provided evidence that GITR signaling renders
CD8+ T cells resistant to suppression by Treg [74]. Hu et al.
utilized recombinant GITRL-Ig fusion protein, which they
found to induce proliferation of CD8+ T cells and Treg,
the latter thereupon loosing their suppressive phenotype.
Moreover, application of GITRL-Ig caused regression of
RENCA and Colon26 tumors in BALB/c mice. Depletion
studies revealed the relevance of CD8+ T cells for the
observedeﬀectsandanincreasednumberofnonregulatoryT
cellsamongtumor-inﬁltratinglymphocyteswereobservedin
GITRL-Ig treated animals [75]. Similar results were observed
by these investigators upon treatment with agonistic GITR
antibody, and meanwhile also multiple other studies have
demonstrated that, beyond enforced GITRL expression or
addition of recombinant GITRL, treatment with agonistic
GITR antibody enhances antitumor immunity in mice. Ko
et al. reported that intravenous or intratumoral adminis-
tration of DTA-1 anti-GITR antibody eradicated established
ﬁbrosarcoma in BALB/c mice without eliciting substantial
autoimmunity. Moreover, mice that had rejected tumors
upon DTA-1 treatment rejected tumors upon rechallenge
with even 10-fold higher tumor cell numbers indicating that
the mice had developed speciﬁc antitumor immunity. In
addition, tumors of mice treated with anti-GITR displayed
large numbers of inﬁltrating activated T cells, and DTA-
1 treatment increased the number of IFN-γ secreting T
cells, which was required for tumor rejection [76]. DTA-1
treatment at the time of inoculation of B16 tumor cells into
C57BL/6 had already been reported by Turk and coworkers
to cause rejection upon a secondary challenge with the same
tumor in the ﬁrst published study suggesting that GITR
could be a target for tumor therapy [77]. In another study,
the same group employed combined vaccination with cancer
self-antigensandanti-GITRantibodyapplicationforanalysisClinical and Developmental Immunology 5
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Figure 1: Consequences of signaling via GITR and GITRL in diﬀerent cell types. Shown are eﬀects on cellular reactions of the indicated
immune eﬀector cells and tumor cells as emerged from the multitude of available studies. It should be noted that for some of the depicted
eﬀector functions diﬀerent or even opposite results have been reported in some studies.
of protection from B16 tumor challenge in C57BL/6 mice
and addressed, among others, the eﬀects of GITR triggering
on CD8+ T cell responses [78]. Enhanced primary and
recall CD8+ T cell responses like increased cell number,
granule mobilization, and IFN-γ production were observed
upon GITR activation during immunization with melanoma
diﬀerentiation antigens, and these eﬀects were only partially
dependentonCD4+Tcells.GITRstimulationwasassociated
with enhanced antitumor immunity, but also resulted in
slight autoimmunity (i.e., hypopigmentation) in this study.
Of note, the eﬀects of anti-GITR application were found to
be dependent on the time point of application during the
immunization, which lends further evidence to the notion
that the eﬀects of GITR stimulation vary with the level
of the immune response. Duan and coworkers found that
treatment of C57BL/6 mice with agonistic GITR antibody
led to regression of B16 tumors transfected to express a
mutated self-antigen, and a marked tumor inﬁltration and
enhanced numbers of CD8+ T cells speciﬁc for the mutated
antigen were observed [79]. Other investigators studied the
eﬀects of anti-GITR on eﬀector functions of CD8+ T cells
from DUC18 donors adoptively transferred into BALB/c
mice carrying CMS5 ﬁbrosarcoma xenotransplants. They
reported enhanced tumor inﬁltration, activation, prolifera-
tion, cytokine production, granule mobilization, and lytic
activity [80]. Ramirez-Montagut and coworkers observed
increased survival upon DTA-1 application in their tumor
models (BALB/c mice injected with RENCA cells and
C57BL/6 mice inoculated with B16 melanoma cells), which
required presence of CD4+ and CD8+ T cells. These inves-
tigators further demonstrated that CD4+ T cells, CD8+ T
cells, or a combination of both, derived from DTA-1 treated
tumor-challenged mice, led to tumor rejection following
adoptive transfer in their model system. They conﬁrmed
the important role of IFN-γ for DTA-1-mediated tumor
rejection and provided evidence that CD178/Fas Ligand,
but not perforin is required for GITR-mediated eﬀects on
antitumor immunity. In addition, this group also reported
generation of T cell memory, mild signs of autoimmunity
in a subset of treated animals, and enhanced activation and
numbers of eﬀector T cells, but also elevated numbers of
Treg. It is of importance that in this study application of
agonistic anti-GITR, besides modulating T cell reactivity,
was also shown to inﬂuence the reactivity of other cell
populations involved in antitumor immunity. Mice depleted
of NK/NKT cells developed tumors rapidly, and application6 Clinical and Developmental Immunology
of DTA-1 had only little eﬀect. This indicates that beyond T
cellsNKand/orNKTcellactivitysubstantiallycontributedto
the immune response induced by GITR stimulation [25]. An
eﬀect of agonistic anti-GITR on immune eﬀector cells other
than T cells was also observed by Zhou et al. They reported
increased numbers and activation of T cells, but also of B
cells and NK cells in draining lymph nodes of CT26 tumor-
bearing BALB/c mice after DTA-1 treatment, and GITR
stimulation enhanced PMA/Ionomycin-induced NK cell
granule mobilization. DTA-1 also increased Treg numbers
andactivation,andnoreductionofTregsuppressivecapacity
but resistance of responder CD4+ T cells to Treg suppression
after in vivo GITR stimulation was observed. They further
performed depletion experiments and reported that tumors
grew faster in CD8+ T cell and NK cell depleted mice.
DTA-1 treatment still mediated signiﬁcant tumor rejection
indicating that neither CD8+ nor NK cells were absolutely
requiredforitseﬃcacy.However,combinedNKandCD8+T
celldepletionsigniﬁcantlycompromisedtheeﬀectsofDTA-1
treatment, which led the investigators to conclude that there
may be a redundant mechanism in tumor killing by these
two cell types. In contrast, CD4+ T cell depletion completely
abrogated the eﬀects of DTA-1 on tumor growth, but also on
activation of CD8+ T cells and NK cells. When interpreting
these data, one should consider that the depletion strategy
employed in this study may not have completely eradicated
the respective cell types, as for example, only about 80% of
NK cells, were successfully depleted [28]. Nevertheless, these
data clearly indicate that various diﬀerent immune eﬀector
cell types interact upon and contribute to eﬀects of anti-
GITR treatment in tumor-bearing mice.
While most studies attributed the eﬀects of DTA-1
treatment in tumor models to the agonistic properties of
thisantibody,tworecentstudiesdemonstratethattheimpact
of DTA-1 treatment in tumor models may also be due to
eﬀects other than GITR triggering. Coe et al. conﬁrmed
the potent antitumor eﬀects of DTA-1 in C57BL/6 mice
xenotransplanted with MB49 bladder carcinoma and found
in ex vivo analyses that Treg of antibody-treated animals
did not display reduced suppressive capacity as compared
to Treg of untreated animals. Using foxp3/GFP knock-in
mice they reported a reduction of tumor-inﬁltrating and
circulating Treg in antibody treated animals. Moreover,
they also observed depletion of monoclonal Treg adoptively
transferred into Thy1.2B6 mice upon DTA-1 treatment
with a more pronounced eﬀect on tumor-inﬁltrating Treg
compared to Treg in draining lymph nodes. GITR expression
was more pronounced on Treg as compared to eﬀector T
cells and on Treg in tumors as compared to Treg of tumor
draining lymph nodes, which led the authors to conclude
that increased GITR expression of tumor-inﬁltrating Treg
rendered them more susceptible to DTA-1 depletion. Thus,
although DTA-1 was described as nondepleting by other
investigators [15, 76], these results indicate that DTA-1 may
be a depleting antibody in vivo which preferentially targets
TregduetotheirhighlevelsofGITRexpression,andthatthis
mechanism contributes to its antitumor eﬃcacy [81]. Cohen
and coworkers demonstrated by analyses in C57BL/6 mice
inoculated with B16 melanoma cells that DTA-1 treatment
is more eﬀective when given several days after tumor
inoculation as compared to antibody treatment and tumor
inoculation at the same day, suggesting that the eﬃcacy of
DTA-1 requires upregulation of GITR on tumor-activated
T cells. They further reported that GITR triggering did not
systemically alter the capacity of Treg or eﬀector T cells to
suppress or to be suppressed. When studying T cell subsets,
they observed a decrease of the Treg frequency within the
tumors following DTA-1 treatment resulting in an altered
eﬀector:regulatory T cell ratio, while this did not occur
in spleens or tumor-draining lymph nodes. Analyses with
adoptively transferred melanoma-speciﬁc T cells revealed
that DTA-1 treatment reduced the accumulation of GITR-
expressing, but not GITR-negative Treg in the tumor, while
numbers in spleen and draining lymph nodes were not
altered. Moreover, cells traﬃcking into the tumor displayed
enhanced eﬀector functions. Using foxp3/GFP mice they
further found that DTA-1 treatment resulted in reduced
Treg foxp3 expression in the tumor, which is indicative for
loss of suppressive function. Finally, the authors provided
evidence that lack of GITR expression on Treg or eﬀector
T cells attenuated the antitumor eﬀect of DTA-1, while
lack of GITR expression on both cell populations abrogated
its eﬀects [82]. Beyond conﬁrming that GITR expression
levels and depletion of GITR-bearing cells inﬂuence the
antitumor eﬀects of DTA-1, the data from these and other
studies indicate that the optimal timing of GITR ligation
may vary in diﬀerent tumor models according to strain and
immunogenicity and aggressiveness of the tumor. However,
it remains yet unclear whether and how depletion of other
GITR-bearing immune eﬀector cells like B cells, NK cells and
monocytes/macrophages upon DTA-1 treatment inﬂuences
antitumor immunity.
While the results obtained in the diﬀerent studies vary
substantially, the overall notion based on the data obtained
in the murine system was that stimulation of GITR may
be a promising approach for treatment of human cancers.
However, data by us and others on the role of GITR in
human NK cells indicate that stimulation of GITR may also
impair antitumor immunity [11,31,33,43]. Ex vivoanalyses
of human tumors from diﬀerent histological origin and
leukemic blasts revealed substantial expression of GITRL,
which was not found in corresponding healthy tissues. In
addition, sera from cancer patients but not from healthy
donors contain substantial levels of sGITRL. Interaction of
tumor-derived GITRL with NK-expressed GITR not only
directly reduced NK cytotoxicity and IFN-γ production, but
also the release of immunoinhibitory cytokines by tumor
cells following reciprocal GITR-GITRL interaction impaired
NK cell antitumor reactivity [11, 31, 43]. Recently we
found evidence for another mechanism by which GITR-
GITRL interaction may negatively aﬀect antitumor immu-
nity in humans. Available data indicate that platelets can
increase metastasis by enabling tumor evasion from NK-
mediated immune surveillance, but the understanding of
the underlying molecular mechanisms was yet fragmentary
at best [83, 84]. We observed that cancer cells of diﬀer-
ent origins (e.g., melanoma, prostate) rapidly get coated by
GITRL-expressing platelets, which confers a seeminglyClinical and Developmental Immunology 7
GITRL-positive phenotype. This “GITRL pseudoexpression”
on platelet-coated tumor cells substantially impairs NK cell
reactivity ([44] and unpublished data). Thus it seems that
expression/pseudoexpression of GITRL may enable tumor
cells to evade immune surveillance by human NK cells,
while a great body of data points to a stimulatory role of
GITR triggering in antitumor immunity in mice. In this
context it is important to bear in mind that species-speciﬁc
diﬀerences following GITR triggering may not only occur
with NK cells. One should also reconsider the available data
with Treg, as suppression of human Treg, in contrast to
their counterparts in mice, does not seem to be inhibited by
GITR [47, 48]. Valuation of the role of GITR in antitumor
immunity thus is complicated because GITR expression
and function may depend on the time point and level
of an ongoing immune response in general as well as on
cellular activity and the respective cell type in particular.
Moreover, while GITR has convincingly been shown to
costimulate eﬀector T cells, T cells from GITR
−/− mice
have been shown to be hyperresponsive to immobilized
anti-CD3 (e.g., references [14, 15, 45, 54]). In addition,
both proapoptotic and antiapoptotic eﬀects relying on
modulation of, for example, Siva (in a Cos7 cell model) or
the CD95/Fas pathway (in T cells) have been reported after
GITR stimulation, which again seem to be dependent on
theactivationstateandthebiologicalenvironment(reviewed
in [85]).
The various signal transduction pathways modulated
by GITR are yet not fully understood (for an excellent
review see [86]). GITR signaling has been shown to involve
ﬁve of the six mammalian TRAF proteins identiﬁed to
date, and activation of the diﬀerent TRAF molecules can
result in varying and even opposite eﬀects, which may, in
addition, diﬀer between mice and men [1, 2, 87–89]. For
example, the two groups that initially identiﬁed human
GITR reported that it positively inﬂuenced NF-κBa c t i v a t i o n
via the TRAF2/NIK pathway while downregulating NF-κB
activityviaTRAF1andTRAF3[1, 2]. Esparza and coworkers
reported, quite in contrast, that murine GITR coexpressed
with TRAF2 reduced NF-κBa c t i v a t i o n[ 88]. In this context,
the recently reported diﬀerence in oligomerization between
human and murine GITRL may also be relevant. It may
result in recruitment of diﬀerent adaptor molecules, which
in turn could explain species-speciﬁc eﬀects of GITR-GITRL
interaction [7–10]. The interpretation of available data on
the function of the GITR-GITRL molecule system and its
modulation in antitumor immunity becomes even more
diﬃcult due to the fact that both GITR and GITRL are
expressed by multiple cell types and can both transduce
signals (Figure 1). Therapeutic intervention thus aﬀects the
reactivity of various diﬀerent immune eﬀector cells involved
in the antitumor immune response, and the consequences
of GITR-GITRL interaction may vary depending on the
involved cell types. Moreover, the eﬀects of therapeutically
modulating GITR by antibodies like DTA-1 or recombinant
ligand do not reﬂect the consequences of GITR interaction
with its natural, tumor-expressed ligand in vivo. This may
explain some of the seemingly contradicting results observed
in diﬀerent studies.
7. Conclusion
Initially considered an inhibitor of Treg activity, GITR
has meanwhile been shown to aﬀect multiple cell types.
Depletion experiments can only partially serve to explain
the mechanisms and consequences of therapeutic GITR
stimulation, as the lack of a certain eﬀector cell popula-
tion may inﬂuence the complex crosstalk of the diﬀerent
components in antitumor immunity. This is even more
since bidirectional signals are mediated following GITR-
GITRL interaction, and studies in GITR
−/− mice have not
yet led to a clear picture of the role of this molecule system
in normal physiology. In addition, the available results
regarding the consequences of GITR stimulation on diﬀerent
T cell subsets and with diﬀerent tumor models have been
found to be inﬂuenced by the time of intervention, the
biologicalenvironment,andtheleveloftheongoingimmune
response. Moreover, they may depend on the aggressiveness
of the respective tumor models. Maybe most important with
regard to the translation of ﬁndings obtained in mouse
modelsintoclinicaltreatmentstrategies,eﬀectsofGITRmay
diﬀerbetweenmiceandmen.Additionalstudiesarerequired
to deﬁne the conditions upon which therapeutic GITR
stimulationactivatesantitumorimmunityinhumans,before
further steps to use GITR/GITRL-modulating reagents for
therapy of cancer patients should be undertaken.
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